Literature DB >> 9706120

Treatment of type 2 diabetes mellitus.

M N Feinglos1, M A Bethel.   

Abstract

Although most patients with type 2 diabetes mellitus can be initially managed with diet and exercise alone, most eventually require at least oral agents if not insulin to maintain glycemic control. Appropriate therapeutic regimens may be difficult to design, given the diversity of drugs available for clinical use. Physicians must consider not only glycemic control, but also patient preference, concomitant medical conditions, and cost when designing therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706120     DOI: 10.1016/s0025-7125(05)70023-7

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  5 in total

Review 1.  Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

2.  3-(4-Bromo-phenyl-sulfon-yl)-8-methyl-1,3-diaza-spiro-[4.5]decane-2,4-dione.

Authors:  M Kalim Kashif; M Khawar Rauf; Michael Bolte; Shahid Hameed
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-18

3.  3-(4-Chloro-phenyl-sulfon-yl)-8-methyl-1,3-diaza-spiro-[4.5]decane-2,4-dione.

Authors:  M Kalim Kashif; M Khawar Rauf; Michael Bolte; Shahid Hameed
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-18

4.  The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study.

Authors:  Per Bech; Robert Moses; Ramón Gomis
Journal:  Qual Life Res       Date:  2003-06       Impact factor: 4.147

Review 5.  A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Authors:  Mozhgan Dorkhan; Anders Frid
Journal:  Vasc Health Risk Manag       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.